FLT3 and acute myeloid leukemia: In this case, the patient had already been treated at the onset of disease using standard Cytarabine–containing regimens with the addition of FLT3 inhibitor Midostaurin, and yet complete response in the bone marrow and cutaneous manifestation of AML occurred simultaneously.